Papers by Wajid Mohammad Sheikh
Clinical Applications of Immunogenetics, 2022
Journal of Medical Virology, 2022
SARS-CoV-2 induces the production of proinflammatory cytokines, which results in cytokine storm, ... more SARS-CoV-2 induces the production of proinflammatory cytokines, which results in cytokine storm, and immune-modulators like Mycobacterium indicus pranii (MIP) might ameliorate COVID -19 related cytokine storm. Therefore, the present study evaluates whether MIP offers an advantage in the treatment of severe COVID -19 patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Prospective MIP cohort Study was conducted in chest disease hospitals in Srinagar, Jammu and Kashmir, India. In the present prospective, randomized clinical study, critically severe COVID -19 patients were divided into two groups, the MIP group (n=105) and Best Standard Treatment group (n=210). Procalcitonin, Ferritin, Hs-CRP (High Sensitive C Reactive Protein), D-dimer levels and Interleukin levels on 5th -day post-treatment were significantly reduced in the MIP group compared to the BST group. Compared to the BST group, 105 consecutive patients with severe COVID -19 in the MIP group reported early weaning off mechanical ventilation, resolution of chest architecture (CT scan), significant increase in SpO2 levels and decreased mortality with hazard ratio-0.234 (95% CI-0.264-2.31) (p-value-0.001). MIP restored SpO2 , immune/inflammatory response, normalized lung abnormalities (Chest CT scan), and reduced mortality without any serious complications. However, there is a need for placebo-controlled double-blind and controlled clinical trials to confirm the efficacy. This article is protected by copyright. All rights reserved.
A Molecular Approach to Immunogenetics, 2022
A Molecular Approach to Immunogenetics, 2022
Journal of Applied Toxicology, 2021
Nanotechnology has revolutionized diverse fields, which include agriculture, the consumer market,... more Nanotechnology has revolutionized diverse fields, which include agriculture, the consumer market, medicine, and other fields. Widespread use of nanotechnology-based products has led to increased prevalence of these novel formulations in the environment, which has raised concerns regarding their deleterious effects. The application of nanotechnology-based formulations into clinical use is hampered by the lack of the availability of effective in vitro systems, which could accurately assess their in vivo toxic effects. A plethora of studies has shown the hazardous effects of nanoparticle-based formulations in two-dimensional in vitro cell cultures and animal models. These have some associated disadvantages when used for the evaluation of nano-toxicity. Organoid technology fills the space between existing two-dimensional cell line culture and in vivo models. The uniqueness of organoids over other systems for evaluating toxicity caused by nano-drug formulation includes them being a co-culture of diverse cell types, dynamic flow within them that simulates the actual flow of nanoparticles within biological systems, extensive cell-cell, cell-matrix interactions, and a tissue-like morphology. Thus, it mimics the actual tissue microenvironment and, subsequently, provides an opportunity to study drug metabolism and toxico-dynamics of nanotechnology-based novel formulations. The use of organoids in the evaluation of nano-drug toxicity is in its infancy. A limited number of studies conducted so far have shown good predictive value and efficiently significant data correlation with the clinical trials. In this review, we attempt to introduce organoids of the liver, lungs, brain, kidney intestine, and potential applications to evaluate toxicity caused by nanoparticles.
Basic & Clinical Pharmacology & Toxicology, 2021
Background: The COVID-19 pandemic has demanded effective therapeutic protocol from researchers an... more Background: The COVID-19 pandemic has demanded effective therapeutic protocol from researchers and clinicians across the world. Currently, a large amount of primary data have been generated from several preclinical studies. At least 300 clinical trials are underway for drug repurposing against COVID-19; the clinician needs objective evidence-based medication to treat COVID-19. Observations: Single-stranded RNA viral genome of SARS-CoV-2 encodes structural proteins (spike protein), non-structural enzymatic proteins (RNA-dependent RNA polymerase, helicase, papain-like protease, 3-chymotrypsin-like protease) and other accessory proteins. These four enzymatic proteins on spike protein are rate-limiting steps in viral replications and, therefore, an attractive target for drug development against SARS-CoV-2. In silico and in vitro studies have identified various potential epitomes as candidate sequences for vaccine development. These studies have also revealed potential targets for drug development and drug repurposing against COVID-19. Clinical trials utilizing antiviral drugs and other drugs have given inconclusive results regarding their clinical efficacy and side effects. The need for angiotensin-converting enzyme (ACE-2) inhibitors/angiotensin receptor blockers and corticosteroids has been recommended. Western countries have adopted telemedicine as an alternative to prevent transmission of infection in the population. Currently, no proven, evidence-based therapeutic regimen exists for COVID-19. Conclusion: The COVID-19 pandemic has put tremendous pressure on researchers to evaluate and approve drugs effective against the disease. Well-controlled randomized trials should assess medicines that are not marketed with substantial evidence of safety and efficacy and more emphasis on time tested approaches for drug evaluation. K E Y W O R D S coronavirus, COVID-19, drug repurposing, in vitro, in vivo and in silico 2 | SHAH et Al. Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia Group A (15) 1*10E6 UC-MSCs /kg body weight suspended in 100 mL saline (Phase-I) Group A (15) 100 mL saline intravenously (Phase-II) Recruiting Last Update Posted:
Phytotherapy Research, 2021
An extensive review of the literature was carried out on antiviral medicinal plants and their ass... more An extensive review of the literature was carried out on antiviral medicinal plants and their associated bioactive compounds between 2019 and 2020 via electronic search Pubmed, Scopus, Web of Science, Science Direct, J-Gate, Google Scholar, and a library search for articles published in peer-reviewed journals. The unpublished materials have been excluded from this review. The review process was further continued by the refining of the search results using the keywords namely viral medicinal plants, antiviral bioactive compounds, emerging viral infections, novel coronavirus, coxsackievirus (CV), dengue virus (DENV), enterovirus 71, human herpes viruses, hepatitis virus, human immunodeficiency virus, influenza virus, measles virus (MV), respiratory syncytial virus (RSV), and rotavirus. The literature cited in the review dated from 1950 to 2020 and limited to the English language. The final data collected through the authors' discussions were then compiled, evaluated, compared, and drawn accordingly.
A Molecular Approach to Immunogenetics, 2022
Uploads
Papers by Wajid Mohammad Sheikh